Antibody Response to SARS-CoV-2 Vaccination in Patients following Allogeneic Hematopoietic Cell Transplantation
| Autor: | Huang, Alice, Cicin-Sain, Caroline, Pasin, Chloé, Epp, Selina, Audigé, Annette, Müller, Nicolas J, Nilsson, Jakob, Bankova, Andriyana, Wolfensberger, Nathan, Vilinovszki, Oliver, Nair, Gayathri, Hockl, Philipp, Schanz, Urs, Kouyos, Roger D, Hasse, Barbara, Zinkernagel, Annelies S, Trkola, Alexandra, Manz, Markus G, Abela, Irene A, Müller, Antonia M S |
|---|---|
| Přispěvatelé: | University of Zurich, Müller, Antonia M S |
| Jazyk: | angličtina |
| Rok vydání: | 2022 |
| Předmět: |
10028 Institute of Medical Virology
COVID-19 Vaccines 2747 Transplantation 2720 Hematology 610 Medicine & health 2700 General Medicine Article 10234 Clinic for Infectious Diseases 1307 Cell Biology Immunology and Allergy Humans BNT162 Vaccine Aged Transplantation SARS-CoV-2 Vaccination Hematopoietic Stem Cell Transplantation COVID-19 Cell Biology Hematology surgical procedures operative 1313 Molecular Medicine Antibody Formation 10032 Clinic for Oncology and Hematology 2723 Immunology and Allergy Molecular Medicine |
| Zdroj: | Transplantation and Cellular Therapy |
| Popis: | Background Vaccines against SARS-CoV-2 have been rapidly approved. While pivotal studies were conducted in healthy volunteers, little information is available on safety and efficacy of mRNA vaccines in immunocompromised patients, including recipients of allogeneic hematopoietic cell transplantations (allo-HCT). Objectives Here, we used a novel assay to analyze patient- and transplant-related factors and their influence on immune responses over an extended period of time (up to 6 months) to the SARS-CoV-2 vaccination in a large and homogenous group of allo-HCT recipients at a single center in Switzerland. Study Design We examined longitudinal antibody responses to SARS-CoV-2 vaccination with BNT162b2 (BioNTech/Pfizer) or mRNA-1273 (Moderna) in 110 allo-HCT recipients and 86 healthy controls. Seroprofiling recording IgG, IgA, and IgM reactivities against SARS-CoV-2 antigens (receptor-binding domain (RBD), spike glycoprotein subunits S1 and S2, and nucleocapsid protein (N)) was performed prior to vaccination, prior to the 2nd dose, and 1, 3, and 6 months (m) after the 2nd dose. Patients were stratified to three groups (A) 3-6m post HCT; (B) 6-12m post HCT; and (C) >12m post HCT. Results Individuals early post allo-HCT (3-6 and 6-12m post HCT) developed significantly lower antibody titers after vaccination compared to patients >12m post allo-HCT and healthy controls (p65 years (p=0.030), those under immunosuppression for prevention or treatment of graft-vs-host disease (GVHD) (p=0.033), and/or with relapsed disease (p=0.014) displayed poor humoral immune response to the vaccine. In contrast, the intensity of the conditioning regimen, underlying disease (myeloid/lymphoid/other), and presence of chronic GVHD had no impact on antibody levels. Antibody titers achieved the highest levels 1m after the 2nd dose of the vaccine but substantially waned in all transplanted groups and healthy controls over time. Conclusions This analysis of long-term vaccine antibody response is of critical importance to allo-HCT recipients and transplant physicians to guide treatment decisions regarding re-vaccination and social behavior during the SARS-CoV-2 pandemic. Graphical Abstract Image, graphical abstract |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|